,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['bcsm', 'db04', 'mbc']
most anticipated: db04 :
- t-dxd significantly os, pfs and orr in her2 low mbc regardless of hr status. - os of ~ 10m in hr-ve mbc and ~ 6m for hr+ve - ild with t-dxd 12% of cases, 3 g5. new soc more hope for our patients. #asco2022 #asco22 #bcsm #db04 
???????? ?? ??????? - ?????? ???????? Medical Oncologist #breastcancer. MD Anderson Alumni “All tweets are my own and RT?endorsement”